Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 10 versus PEMOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 10 versus PEMOLINE.
DYANAVEL XR 10 vs PEMOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Pemoline is a central nervous system stimulant that enhances dopaminergic and noradrenergic transmission by blocking the reuptake of dopamine and norepinephrine at the synaptic cleft. It also has mild monoamine oxidase inhibitory activity.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
Oral, 37.5 mg once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day (divided into 2 doses if total dose > 75 mg).
None Documented
None Documented
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Terminal elimination half-life is 8-12 hours in children; 12-16 hours in adults. Steady-state is reached within 2-3 days.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Pemoline is primarily excreted renally as unchanged drug (40-50%) and metabolites; approximately 20-30% is excreted in feces via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant